A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.

Abstract

Long-term survival in epithelial ovarian cancer remains problematic despite multimodality therapy. A fundamental difficulty is the development of tumor resistance to platinum compounds. Analogs have been developed that demonstrate activity in platinum-resistant cell lines both in vitro and in vivo. Lobaplatin (D-19466), a third-generation compound, demonstrates significant activity in carboplatin and cisplatin-resistant cell lines. Lobaplatin was given to 17 assessable patients with platinum-refractory ovarian cancer. The drug was initially administered at a dose of 50 mg/m2 but was later reduced to 40 mg/m2 because of excessive thrombocytopenia. Nine patients required red cell transfusions during therapy. Cycles were repeated every 21-35 days (median cycle length 28 days). No objective responses were observed. Lobaplatin has no activity in platinum-resistant epithelial ovarian cancer.

• Authors: J J Kavanagh, C L Edwards, R S Freedman, M B Finnegan, O Balat, D Tresukosol, K Burk, S Loechner, M Hord, J L Franklin
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 58 Issue 1 Pg. 106-9 (Jul 1995) ISSN: 0090-8258 [Print] United States
• PMID: 7789874 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antineoplastic Agents
• Cyclobutanes
• Organoplatinum Compounds
• Platinum
• lobaplatin

Topics

• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Cyclobutanes (therapeutic use)
• Drug Resistance
• Female
• Humans
• Middle Aged
• Organoplatinum Compounds (therapeutic use)
• Ovarian Neoplasms (drug therapy)
• Platinum (therapeutic use)